biostudies-literatureAntunes LEuropean Centre for Disease Prevention and Controle70081https://www.ebi.ac.uk/biostudies/studies/S-EPMC11890973biostudies-literatureUnknown19(3)We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.Influenza and other respiratory virusesEffectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024.PMC11890973ECDC/2021/016 (EU-H)ECDC/2021/016 (EU‐H)Cikes MPreuss UDuffy RMladinov SKrisztalovics KKosa-Tudor AGAndry LDelaere BBauer TBlommen MMartinez-Baz INonkovic DSion CBorg MLHusa PNavascues AMedic ANovosel IPTomas ILuca MCJancoriene LTavares MCesar HCGuiomar RBourgeois MMickiene ABarbara Cde Lacerda APDe Waegemaeker PTolksdorf KTuri GVEBIS SARI VE network teamDe Koster SHoward JDockx YDurrwald RParys AVarga CMaia E Silva SCBleyen MDomegan LVerdasca NDenayer SCincileviciute GFlorescu SABasile LDinu STrobajo-Sanmartin CBuda SSouckova LPetric PTRojas-Castro MXuereb GPereira DVilain AJukic INicolay NSeyler LPascu CNecsoi CDauby NDziugyte ADorobat CMFernandez-Huerta MLeroux-Roels IRodrigues APTabain IMarin ANaesens ROprea MToure YBacci SKrieger DEzpeleta CKarabuva SHolemans XGeeroms SPinto PEzpeleta GHenriques CTernest SZablockiene BBrugerolles CBossuyt NMakaric ZLCenoz MGMelillo TKubiliute ITardei GOh DYHackmann CFatukasi TReynders MDemuyser TFitzgerald MDaelemans SPetrovic GAntunes LMlinaric IRadas JMarkic JDelvallee MSlekyte GJouck DMajauskaite FCasado IPopescu CLoghin IIJansens HVaikutyte RKuliese MRose AMCBistriceanu IMachado AFenyves BOroszi BStruyven PMihai MEHorvath JKZablockis RBernaert EMagerman KCeausu EBrnas ACastilla JReiche JWitdouck ADufrasne FJuhasz KMVan Nedervelde EAbela SLozano MTonkic MBocina IGomez VIvanciuc ALazar MNikolic MEcheverria AMatheeussen VMartin CDe Mot LPetit EKristof KCauchi JPO'Donnell JLissoir BFierens SfalseEffectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024.We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case-control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14-59 days and 34% at 60-119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.2025-01-01T00:00:00Z2025 Mar2025-06-27T03:05:41.416Z2025-04-04T08:23:12.097ZS-EPMC118909734005906910.1111/irv.70081